Chen S, Sanjana NE, Zheng K, et al. Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell. 2015;160(6):1246-60. doi:10.1016/j.cell.2015.02.038
Tengs T, Lee JC, Paez G, et al. A transforming MET mutation discovered in non-small cell lung cancer using microarray-based resequencing. Cancer Lett. 2006;239(2):227-33. doi:10.1016/j.canlet.2005.08.007
Kim Y, Hammerman PS, Kim J, et al. Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients. J Clin Oncol. 2014;32(2):121-8. doi:10.1200/JCO.2013.50.8556
Niederst MJ, Sequist LV, Poirier JT, et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat Commun. 2015;6:6377. doi:10.1038/ncomms7377
Sweet-Cordero A, Mukherjee S, Subramanian A, et al. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet. 2005;37(1):48-55. doi:10.1038/ng1490
Berger AH, Imielinski M, Duke F, et al. Oncogenic RIT1 mutations in lung adenocarcinoma. Oncogene. 2014;33(35):4418-23. doi:10.1038/onc.2013.581
Cai Y, Hirata A, Nakayama S, et al. CCAAT/enhancer binding protein β is dispensable for development of lung adenocarcinoma. PLoS One. 2015;10(3):e0120647. doi:10.1371/journal.pone.0120647
Halmos B, Bassères DS, Monti S, et al. A transcriptional profiling study of CCAAT/enhancer binding protein targets identifies hepatocyte nuclear factor 3 beta as a novel tumor suppressor in lung cancer. Cancer Res. 2004;64(12):4137-47. doi:10.1158/0008-5472.CAN-03-4052
Shi J, Marconett CN, Duan J, et al. Characterizing the genetic basis of methylome diversity in histologically normal human lung tissue. Nat Commun. 2014;5:3365. doi:10.1038/ncomms4365
Johnston AJ, Murphy KT, Jenkinson L, et al. Targeting of Fn14 Prevents Cancer-Induced Cachexia and Prolongs Survival. Cell. 2015;162(6):1365-78. doi:10.1016/j.cell.2015.08.031